Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRTH-101 Alone or With Pembrolizumab in Advanced Solid Tumors
NCT05753722Phase 1Completed
- Sponsor
- Incendia Therapeutics
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRTH-101 in solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Incendia Therapeutics. Primary endpoints: Adverse Events at 4 years, Maximum Tolerated Dose at 4 years and 2 more. Started Mar 2023; status: completed.
02
Drugs
PRTH-101
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05753722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753722.